

Adam S Cheifetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5272211/publications.pdf>

Version: 2024-02-01

180
papers

7,238
citations

50276

46
h-index

64796

79
g-index

180
all docs

180
docs citations

180
times ranked

7056
citing authors

#	ARTICLE	IF	CITATIONS
1	Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2023, 164, 164-165.	1.3	4
2	Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 465-467.e2.	4.4	17
3	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	8.1	57
4	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	2.3	0
5	Choosing the right biologic for complications of inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 235-249.	3.0	3
6	Review article: emerging drug therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 789-804.	3.7	38
7	Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1049-1050.	3.7	2
8	Letter: is blindly stopping thiopurines without confirming adequate anti-TNF concentrations shortsighted?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 887-888.	3.7	0
9	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). <i>BMJ Open</i> , 2022, 12, e057656.	1.9	17
10	Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 406-414.	1.5	2
11	Therapeutic Drug Monitoring of Biologics in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 299-317.	2.2	8
12	PUCCINI: Safety of Anti-TNF in the Perioperative Setting. <i>Gastroenterology</i> , 2022, 163, 44-46.	1.3	2
13	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	4.4	15
14	Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 940-946.	1.9	6
15	Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 854-855.	4.4	3
16	Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	3
17	Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1785-1786.	1.3	0
18	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1552-1563.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1129-1135.	0.9	8
20	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2014-2025.	0.4	93
21	Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1085-1086.	3.7	1
22	Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1067.	7.4	1
23	Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1007-1014.	0.4	31
24	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021, 10, 5642.	2.4	4
25	Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1423-1431.	3.3	5
26	Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 103-111.	1.9	34
27	Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 878-879.	1.3	3
28	Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3142.	2.4	17
29	Evidence Supporting High-Dose Use of Biologics in Clinical Practice. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 408-422.	0.8	2
30	Endogenous antisense RNA curbs CD39 expression in Crohn's disease. <i>Nature Communications</i> , 2020, 11, 5894.	12.8	16
31	Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. <i>Journal of Clinical Medicine</i> , 2020, 9, 2840.	2.4	2
32	Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. <i>Current Opinion in Rheumatology</i> , 2020, 32, 371-379.	4.3	19
33	Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon Cancer. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1319-1329.	1.9	48
34	Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1445-1450.	1.9	10
35	Response. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 719-720.	1.0	1
36	New role for azathioprine in case of switching anti-TNFs in IBD. <i>Gut</i> , 2020, 69, 1165-1167.	12.1	6

#	ARTICLE	IF	CITATIONS
37	A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflammatory Bowel Diseases, 2020, 26, e59-e61.	1.9	3
38	Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?. Digestive Diseases and Sciences, 2019, 64, 2736-2739.	2.3	7
39	Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease—results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2019, 50, 599-600.	3.7	2
40	Tu1830 — Infiximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients with Inflammatory Bowel Disease. Gastroenterology, 2019, 156, S-1141.	1.3	2
41	Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?. Gastroenterology, 2019, 157, 922-924.	1.3	5
42	Infiximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflammatory Bowel Diseases, 2019, 25, e143-e145.	1.9	13
43	Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 976-981.	1.3	104
44	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Review of Clinical Immunology, 2019, 15, 837-848.	3.0	71
45	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. GastroHep, 2019, 1, 108-117.	0.6	3
46	Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointestinal Endoscopy, 2019, 90, 186-195.e1.	1.0	80
47	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
48	Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Digestive Diseases and Sciences, 2019, 64, 1397-1398.	2.3	0
49	Infiximab in inflammatory bowel disease. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231983844.	2.5	82
50	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1217-1226.	1.3	7
51	The cost and benefit of anti-TNF therapy from a population perspective—for what it's worth. Annals of Translational Medicine, 2019, 7, S388-S388.	1.7	0
52	Therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Gastroenterology, 2019, 35, 302-310.	2.3	42
53	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 139-147.	4.4	138
54	The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflammatory Bowel Diseases, 2019, 25, 998-1005.	1.9	13

#	ARTICLE	IF	CITATIONS
55	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 427-435.	1.9	36
56	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. <i>Clinical Immunology</i> , 2019, 206, 9-14.	3.2	63
57	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 656-665.	0.1	15
58	Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 465-466.	1.9	0
59	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1829-1831.	4.4	4
60	Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 436-437.	3.7	0
61	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. <i>Gastroenterology</i> , 2018, 154, 1201-1202.	1.3	20
62	Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 761-767.	2.3	21
63	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	273
64	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 191-197.	1.9	33
65	Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2266-2271.	1.9	65
66	Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 804-810.	1.3	91
67	Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg ⁻) on anti-TNF therapy have a low rate of reactivation. <i>Clinical Immunology</i> , 2018, 191, 59-62.	3.2	16
68	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 598-599.	4.4	0
69	Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. <i>Digestive Diseases and Sciences</i> , 2018, 63, 36-45.	2.3	9
70	Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3067-3073.	2.3	54
71	The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2018, 14, 415-425.	0.1	11
72	Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. <i>American Journal of Gastroenterology</i> , 2017, 112, 673-676.	0.4	50

#	ARTICLE	IF	CITATIONS
73	Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1580-1588.e3.	4.4	181
74	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1113-1123.	1.3	17
75	Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 721-726.	1.9	33
76	Crohn Disease: Epidemiology, Diagnosis, and Management. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1088-1103.	3.0	292
77	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1638-1639.	4.4	0
78	Editorial: therapeutic de-escalation of anti-tumor necrosis factor therapy "is less enough?". <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1265-1266.	3.7	1
79	Inflammatory Bowel Disease-Related Abstracts Presented at National Conferences in the USA Are Frequently Unpublished as Full Manuscripts. <i>Digestive Diseases and Sciences</i> , 2017, 62, 352-357.	2.3	2
80	Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?. <i>Digestive and Liver Disease</i> , 2017, 49, 1332-1333.	0.9	3
81	Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1510-1515.	1.9	62
82	C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. <i>Journal of Digestive Diseases</i> , 2017, 18, 678-683.	1.5	2
83	Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 415-429.e15.	1.3	114
84	Response to Reinink. <i>American Journal of Gastroenterology</i> , 2017, 112, 1893-1894.	0.4	0
85	Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. <i>World Journal of Gastroenterology</i> , 2017, 23, 6197.	3.3	10
86	Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 556-559.	0.1	4
87	Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. <i>Annals of Gastroenterology</i> , 2016, 29, 341-7.	0.6	23
88	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1418-1424.	1.9	21
89	Utility of Emergency Department Use of Abdominal Pelvic Computed Tomography in the Management of Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 859-864.	2.2	4
90	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. <i>Gastroenterology</i> , 2016, 151, 710-723.e2.	1.3	51

#	ARTICLE	IF	CITATIONS
91	Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1391-1396.	1.9	29
92	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	4.4	36
93	How to Develop the Medical Neighborhood. <i>Journal of Medical Systems</i> , 2016, 40, 196.	3.6	4
94	Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2812-2822.	2.3	13
95	Factors Associated with the Success of In Vitro Fertilization in Women with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2381-2388.	2.3	12
96	Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 507-509.	1.3	10
97	Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 421-428.e2.	4.4	33
98	Use of anti-TNF drug levels to optimise patient management. <i>Frontline Gastroenterology</i> , 2016, 7, 289-300.	1.8	88
99	Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelines. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 379-385.	3.4	18
100	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2806-2814.	1.9	46
101	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2873-2878.	1.9	18
102	Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1176-1186.	1.9	12
103	Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2130-2136.	1.9	21
104	Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency Department. <i>Inflammatory Bowel Diseases</i> , 2015, 21, E21.	1.9	0
105	Biologic Concentration Testing in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	56
106	In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 792-797.	0.4	51
107	Documented Compliance with Inflammatory Bowel Disease Quality Measures Is Poor. <i>Digestive Diseases and Sciences</i> , 2015, 60, 339-344.	2.3	19
108	In Vitro Fertilization in Women With Inflammatory Bowel Disease Is as Successful as in Women From the General Infertility Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1641-1646.e3.	4.4	28

#	ARTICLE	IF	CITATIONS
109	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti- α -Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2233-2240.e2.	4.4	109
110	Utility of CT in the Emergency Department in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 793-800.	1.9	15
111	It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2384.	4.4	3
112	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. <i>American Journal of Gastroenterology</i> , 2014, 109, 1850-1855.	0.4	21
113	Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1708.	7.4	0
114	A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndrome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1735-1739.	1.3	6
115	Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 351-355.	2.2	10
116	Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1996-2003.	1.9	198
117	The Burden of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 545-552.	1.9	106
118	Vitamin D Levels in Adults with Crohn's Disease Are Responsive to Disease Activity and Treatment. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 856-860.	1.9	56
119	High Self-efficacy Predicts Adherence to Surveillance Colonoscopy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1602-1610.	1.9	12
120	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Interventional Medicine Subspecialty Guidelines. <i>Mayo Clinic Proceedings</i> , 2014, 89, 16-24.	3.0	36
121	CD39 and CD161 Modulate Th17 Responses in Crohn's Disease. <i>Journal of Immunology</i> , 2014, 193, 3366-3377.	0.8	79
122	Ulcerative Colitis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1553-1563.	3.0	236
123	Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). <i>Gastroenterology Clinics of North America</i> , 2014, 43, 543-563.	2.2	35
124	Colonoscopy Is Appropriately Utilized In Most Cases Following a Fair Bowel Prep. <i>American Journal of Gastroenterology</i> , 2014, 109, 1289.	0.4	0
125	The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 103-117.	0.8	28
126	In reply "Clinical Practice Guidelines: Still Miles to Go". <i>Mayo Clinic Proceedings</i> , 2014, 89, 860-861.	3.0	0

#	ARTICLE	IF	CITATIONS
127	Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease. PLoS ONE, 2014, 9, e87956.	2.5	54
128	Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 15-22.	1.9	211
129	Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission. Clinical Gastroenterology and Hepatology, 2013, 11, 991-996.	4.4	109
130	Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 40-47.	0.4	298
131	The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2013, 37, 786-794.	3.7	96
132	Management of Active Crohn Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2150.	7.4	118
133	Prevalence and Lifetime Risk of Endoscopy-related Complications Among Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 1288-1293.	4.4	17
134	Evaluation of the small bowel in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2013, 7, 239-251.	3.0	6
135	Lectin-reactive Anti-Î±-Gal in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2796-2800.	1.9	1
136	Commentary: irritable bowel syndrome and the <sc>CDAI</sc> â€“ misleading activity by straw men; authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 1021-1022.	3.7	0
137	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice Guidelines. American Journal of Gastroenterology, 2013, 108, 1686-1693.	0.4	23
138	Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission. Inflammatory Bowel Diseases, 2013, 19, 779-784.	1.9	71
139	Factors that Affect Adherence to Surveillance Colonoscopy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 534-539.	1.9	45
140	Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. Inflammatory Bowel Diseases, 2013, 19, 2457-2463.	1.9	22
141	P-084â€fSelf-Reported Health Maintenance Behaviors in a Population of Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, S58-S59.	1.9	2
142	Varicella zoster virus infection in patients with inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 56-8.	0.1	4
143	Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated with Drug Discontinuation. Journal of Rheumatology, 2012, 39, 1500-1502.	2.0	2
144	Mycobacterium marinum : An Increasingly Common Opportunistic Infection in Patients on Infliximab. American Journal of Gastroenterology, 2012, 107, 1268-1269.	0.4	18

#	ARTICLE	IF	CITATIONS
145	<scp>CD</scp>73 is a phenotypic marker of effector memory <scp>T</scp>h17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , 2012, 42, 3062-3072.	2.9	50
146	Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 405-407.	3.0	0
147	Abdominal phlegmons in Crohn's disease: Outcomes following antitumor necrosis factor therapy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 691-696.	1.9	42
148	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1057-1063.	1.9	48
149	Doctor Message Can Alter Patients' Behavior and Attitudes Regarding Inflammatory Bowel Disease and Colon Cancer. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1531-1539.	1.9	11
150	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1608-1616.	1.9	36
151	Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2294-2300.	1.9	10
152	Varicella zoster virus infection in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2392-2403.	1.9	87
153	Capsule endoscopy for small-bowel evaluation in Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 167-175.	1.0	51
154	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 107-112.	2.2	66
155	Infliximab decreases colectomy rates in moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1626-1628.	1.9	3
156	Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E109-E110.	1.9	4
157	Cryptosporidiosis masquerading as a Crohn's flare. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E133-E134.	1.9	3
158	Vaccination in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, 168.	0.4	1
159	Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1413-1420.	2.3	18
160	The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 655-659.	4.4	46
161	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis - A prospective study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 171-175.	1.3	30
162	Targeting TNF in postoperative recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1925-1926.	1.9	1

#	ARTICLE	IF	CITATIONS
163	Management of acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 395-405.	3.0	25
164	Meta-Analysis of the Placebo Response in Ulcerative Colitis. Digestive Diseases and Sciences, 2008, 53, 875-891.	2.3	23
165	Melanin-concentrating hormone as a mediator of intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10613-10618.	7.1	59
166	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. Gastroenterology and Hepatology, 2008, 4, 713-20.	0.1	0
167	Response to Dr. Spada and Colleagues. American Journal of Gastroenterology, 2007, 102, 1543-1544.	0.4	2
168	Reducing the Torment of Diarrhea. Journal of Clinical Gastroenterology, 2007, 41, 797-798.	2.2	7
169	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2. Gut, 2007, 56, 1210-1217.	12.1	60
170	Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis. Drugs, 2006, 66, 2059-2065.	10.9	14
171	Capsule Endoscopy Retention: Is it a Complication?. Journal of Clinical Gastroenterology, 2006, 40, 688-691.	2.2	110
172	Thyroid cancer and Crohn's disease: Association or coincidence?. Inflammatory Bowel Diseases, 2006, 12, 79-80.	1.9	5
173	Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 82-88.	1.9	31
174	The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 2218-2222.	0.4	358
175	Infliximab: Use in inflammatory bowel disease. Current Treatment Options in Gastroenterology, 2005, 8, 187-196.	0.8	30
176	Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mount Sinai Journal of Medicine, 2005, 72, 250-6.	1.9	94
177	You Say Goodbye and I Say Aloe. , 2004, 10, 693-695.		0
178	Failure to Induce Oral Tolerance in Crohn's and Ulcerative Colitis Patients: Possible Genetic Risk. Annals of the New York Academy of Sciences, 2004, 1029, 225-238.	3.8	31
179	The Diagnosis and Treatment of Pouchitis in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2004, 38, S44-S50.	2.2	49
180	The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience. American Journal of Gastroenterology, 2003, 98, 1315-1324.	0.4	442